## **Core Concept**
Pulmonary embolism (PE) is a condition where a blood clot blocks one of the pulmonary arteries, leading to potential life-threatening complications. Fibrinolytic therapy, also known as thrombolytic therapy, is a treatment approach aimed at dissolving the clot. This therapy involves the administration of drugs that activate plasminogen to form plasmin, which then breaks down fibrin clots.

## **Why the Correct Answer is Right**
Fibrinolytic therapy works by activating the body's own fibrinolytic system to dissolve the thrombus (clot) that is causing the pulmonary embolism. The primary mechanism involves the conversion of plasminogen to plasmin by fibrinolytic agents like alteplase, streptokinase, or urokinase. Plasmin then degrades the fibrin within the clot, leading to its dissolution. This process helps in rapidly restoring blood flow through the obstructed pulmonary artery, which can be lifesaving in severe cases of PE.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while bleeding is a risk, it does not directly relate to the therapeutic effect of fibrinolytic therapy on the clot itself.
- **Option B:** Although changes in blood pressure may occur, this option does not specifically address the primary mechanism or purpose of fibrinolytic therapy in treating pulmonary embolism.
- **Option C:** This option might seem plausible due to the risk of bleeding with fibrinolytic therapy, but it does not accurately describe the therapeutic effect of fibrinolytic therapy on pulmonary embolism.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that fibrinolytic therapy is typically reserved for patients with hemodynamically unstable pulmonary embolism or those with high-risk features, due to its associated risk of bleeding. A classic exam-relevant point is to remember that the main goal of fibrinolytic therapy in PE is to rapidly dissolve the clot and restore pulmonary blood flow.

## **Correct Answer:** . Dissolving the clot.